Successful Treatment of Concomitant Pleural Mucosa-Associated Lymphoid Tissue Lymphoma and Monoclonal Gammopathy of Undetermined Significance with Lenalidomide, Rituximab, and Dexamethasone

Overview

Journal Case Rep Hematol

Publisher Wiley

Specialty Hematology

Date 2022 Jun 9

PMID 35677530

Authors

Yoshiki Uemura

Risa Maeda

Hiroyoshi Saegusa

Affiliations

Soon will be listed here.

Abstract

Concomitant plasma cell and B cell neoplasms in a single patient have been infrequently reported. It is known that the prognosis of these patients is worse than that of patients with single-disease onset. Generally, the chemotherapy specific for each disease is provided sequentially. It has been suggested that the specific chemotherapy for lymphoma could lead to the occurrence of refractory multiple myeloma (MM). We present a case with the concomitant occurrence of mucosa-associated lymphoid tissue (MALT) lymphoma and monoclonal gammopathy of undetermined significance (MGUS). MGUS does not usually require aggressive treatment. However, the potential adverse effects of MGUS on the treatment course of the B cell lymphoma were concerning. Therefore, we explored a new therapeutic approach that is simultaneously effective against both diseases. Combination therapy of lenalidomide (LEN) and rituximab (RIT) gained indication for follicular lymphoma and MALT lymphoma recently. LEN is also a key drug in MM treatment. Both diseases in our patient were effectively treated with the combination of LEN, RIT, and dexamethasone. With this combination therapy, we expect a prognostic improvement in concomitant MM and B cell lymphoma cases.

References

Kuo S, Cheng A, Lin C, Hsu C, Wu M, Yeh K . t(11;18)(q21;q21) translocation as predictive marker for non-responsiveness to salvage thalidomide therapy in patients with marginal zone B-cell lymphoma with gastric involvement. Cancer Chemother Pharmacol. 2011; 68(6):1387-95. DOI: 10.1007/s00280-011-1631-y. View

Tursi A, Modeo M . Monoclonal gammopathy of undetermined significance predisposing to Helicobacter pylori-related gastric mucosa-associated lymphoid tissue lymphoma. J Clin Gastroenterol. 2002; 34(2):147-9. DOI: 10.1097/00004836-200202000-00009. View

Hurez D . [Epidemiology of monoclonal gammopathies]. Rev Prat. 1993; 43(3):271-4. View

Li T, Tan J, Chen L, Kuang D, Mao X, Lou Y . Case report: simultaneous occurrence of multiple myeloma and non-Hodgkin lymphoma treated by CAR T therapy. Medicine (Baltimore). 2020; 99(16):e19739. PMC: 7220358. DOI: 10.1097/MD.0000000000019739. View

Leonard J, Trneny M, Izutsu K, Fowler N, Hong X, Zhu J . AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma. J Clin Oncol. 2019; 37(14):1188-1199. PMC: 7035866. DOI: 10.1200/JCO.19.00010. View

Korde N, Kristinsson S, Landgren O . Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies. Blood. 2011; 117(21):5573-81. PMC: 3316455. DOI: 10.1182/blood-2011-01-270140. View

Wohrer S, Raderer M, Streubel B, Chott A, Drach J . Concomitant occurrence of MALT lymphoma and multiple myeloma. Ann Hematol. 2004; 83(9):600-3. DOI: 10.1007/s00277-004-0870-y. View

Quintanilla-Martinez L, Adam P, Fend F . [In situ lymphoma and other early stage malignant non-Hodgkin lymphomas]. Pathologe. 2013; 34(3):244-53. DOI: 10.1007/s00292-013-1748-3. View

Pasqualetti P, Festuccia V, Collacciani A, Casale R . The natural history of monoclonal gammopathy of undetermined significance. A 5- to 20-year follow-up of 263 cases. Acta Haematol. 1997; 97(3):174-9. DOI: 10.1159/000203676. View

10.

Rajkumar S, Jacobus S, Callander N, Fonseca R, Vesole D, Williams M . Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 2009; 11(1):29-37. PMC: 3042271. DOI: 10.1016/S1470-2045(09)70284-0. View

11.

Kiesewetter B, Troch M, Dolak W, Mullauer L, Lukas J, Zielinski C . A phase II study of lenalidomide in patients with extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT lymphoma). Haematologica. 2012; 98(3):353-6. PMC: 3659944. DOI: 10.3324/haematol.2012.065995. View

12.

Bakkus M, Heirman C, Van Riet I, Van Camp B, Thielemans K . Evidence that multiple myeloma Ig heavy chain VDJ genes contain somatic mutations but show no intraclonal variation. Blood. 1992; 80(9):2326-35. View

13.

Isaacson P, Spencer J, Finn T . Primary B-cell gastric lymphoma. Hum Pathol. 1986; 17(1):72-82. DOI: 10.1016/s0046-8177(86)80157-5. View

14.

Novak U, Basso K, Pasqualucci L, Dalla-Favera R, Bhagat G . Genomic analysis of non-splenic marginal zone lymphomas (MZL) indicates similarities between nodal and extranodal MZL and supports their derivation from memory B-cells. Br J Haematol. 2011; 155(3):362-5. DOI: 10.1111/j.1365-2141.2011.08841.x. View